-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azenosertib in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Epithelial Ovarian Cancer Drug Details: Azenosertib (ZNC-3) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ribociclib Succinate in Oligodendroglioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ribociclib Succinate in Oligodendroglioma Drug Details: Ribociclib succinate (Kisqali, Kryxana) is an antineoplastic agent. It...
-
Product Insights
NewNet Present Value Model: Verrica Pharmaceuticals Inc’s Ycanth
Empower your strategies with our Net Present Value Model: Verrica Pharmaceuticals Inc's Ycanth report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Ocugen Inc’s OCU-400
Empower your strategies with our Net Present Value Model: Ocugen Inc's OCU-400 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Evelo Biosciences Inc’s EDP-1815
Empower your strategies with our Net Present Value Model: Evelo Biosciences Inc's EDP-1815 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EDP-305 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EDP-305 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: EDP-305 is under development for the treatment...
-
Product Insights
NewNet Present Value Model: Enanta Pharmaceuticals Inc’s EDP-305
Empower your strategies with our Net Present Value Model: Enanta Pharmaceuticals Inc's EDP-305 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
UFV Monte Verde Solar II PV Park
UFV Monte Verde Solar II PV Park is a solar PV project located in Rio Grande do Norte, Brazil. The project is owned by EDP Renovaveis Brasil SA; EDP Renovaveis SA and is developed by EDP Renovaveis Brasil SA. The project is at the permitting stage. Empower your strategies with our UFV Monte Verde Solar II PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will...
-
Product Insights
UFV Monte Verde Solar IV PV Park
UFV Monte Verde Solar IV PV Park is a solar PV project located in Rio Grande do Norte, Brazil. The project is owned by EDP Renovaveis Brasil SA; EDP Renovaveis SA and is developed by EDP Renovaveis Brasil SA. The project is at the permitting stage. Empower your strategies with our UFV Monte Verde Solar IV PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will...
-
Product Insights
UFV Monte Verde Solar V PV Park
UFV Monte Verde Solar V PV Park is a solar PV project located in Rio Grande do Norte, Brazil. The project is owned by EDP Renovaveis Brasil SA; EDP Renovaveis SA and is developed by EDP Renovaveis Brasil SA. The project is at the permitting stage. Empower your strategies with our UFV Monte Verde Solar V PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will...